P1856Percutaneous mitral edge-to-edge valvuloplasty in end-stage heart failure as a bridge to heart transplant: a case series from a single tertiary referral center

Abstract Background Improved outcomes after percutaneous edge-to-edge mitral valvuloplasthy with MitraClip implantation were recently observed in patients with heart failure (HF) and functional severe mitral regurgitation (MR). Nonetheless, its efficacy in end-stage heart failure (HF) are lacking. P...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2019-10, Vol.40 (Supplement_1)
Hauptverfasser: Montalto, C, Crimi, G, Mandurino-Mirizzi, A, Frassica, R, Gazzoli, F, Covi, R, Moschella, M, Ghio, S, Magrini, G, Raineri, C, Pelenghi, S, Ferrario, M, De Ferrari, G M, Oltrona-Visconti, L
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title European heart journal
container_volume 40
creator Montalto, C
Crimi, G
Mandurino-Mirizzi, A
Frassica, R
Gazzoli, F
Covi, R
Moschella, M
Ghio, S
Magrini, G
Raineri, C
Pelenghi, S
Ferrario, M
De Ferrari, G M
Oltrona-Visconti, L
description Abstract Background Improved outcomes after percutaneous edge-to-edge mitral valvuloplasthy with MitraClip implantation were recently observed in patients with heart failure (HF) and functional severe mitral regurgitation (MR). Nonetheless, its efficacy in end-stage heart failure (HF) are lacking. Purpose Our aim was to investigate feasibility, preliminary efficacy on hemodynamics and follow-up of MitraClip implantation in a cohort of patients with very advanced HF. Methods Patients were retrospectively included in the present analysis if already in HT list, unsuitable for HT despite optimal medical and device therapy, or if implantation was a “bridge-to-candidacy”. Results Baseline and procedural characteristics are listed in Table 1; MR etiology was predominantly functional (n=7). No major complications were observed in the peri-operative period. At 6-month follow-up, invasive hemodynamics was available for 8 patients. A significant increase in cardiac index was observed (Least Square Mean Difference, LSMD = +0.47 L/min/m2; p=0.03; Figure 1), in conjunction with a numerical reduction in pulmonary vascular resistance (LSMD = −1.02 WU; p=0.3), a trend towards lower mean pulmonary arterial pressure (LSMD = −6.5 mmHg; p=0.053) and lower ejection fraction (LSMD = −6.5%; p=0.053). At a median follow-up of 772 days (IQR 156–1,578), all three patients unsuitable for HT at baseline could be eligible to HT list and one of them received LVAD. Moreover, two patients were transplanted, four experienced unplanned rehospitalization for HF, and one died of non-cardiac cause. Table 1. Baseline clinical evaluation (n=10) Age (y) 53.67±8.43 HF Etiology – post ischemic 4 (40) Male sex 6 (60) HF Etiology – no CAD 4 (40) Body Surface Area (m2) 1.76±0.22 HF Etiology – other 2 (20) Chronic Resynchronization Therapy 5 (50) Euroscore II 6.00±2.74 Baseline MR grade (+) 4 (40) STS mortality 1.71±2.65 Residual MR grade (+) 1.71±0.49 Clips implanted (number) 1.78±0.67 Data are expressed as mean ± SD or count (valid %). MR scored on a scale from 0+ to 4+. STS, Society of Thoracic Surgeons. Figure 1 Conclusions Percutaneous edge-to-edge mitral valvuloplasty with MitraClip appears safe and effective in end-stage patients, impacts on clinical decision-making and therefore might be considered as a “bridge” towards a more definite strategy. Acknowledgement/Funding None
doi_str_mv 10.1093/eurheartj/ehz748.0607
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehz748_0607</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehz748.0607</oup_id><sourcerecordid>10.1093/eurheartj/ehz748.0607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c877-2e804442eab659a2dfe54945b9fb3273bf8c0496e33d2589fdbff3647b1297093</originalsourceid><addsrcrecordid>eNqNkE1qwzAQRkVpoWnaIxR0ASWSLMlWdyX0DwLNIovujGyPEgXHDpJcSM_Tg1ZuQtddDczHm_l4CN0zOmNUZ3MY_BaMj7s5bL9yUcyoovkFmjDJOdFKyEs0oUxLolTxcY1uQthRSgvF1AR9r1gh1Qp8PUTTQT8EvHfRmxZDswESezJO_Gnaz6HtD60J8Yhdh6FrSIgmRb-vsTWuHTxgE7DBlXcjFPtzmO51IbFdfEhpbQLgAN5BwNb3-7QKrtu0CQAfnfFH7MGCH0vU0KXlLbqypg1wd55TtH5-Wi9eyfL95W3xuCR1keeEQ0GFEBxMpaQ2vLEghRay0rbKeJ5Vtqip0AqyrOGy0LaprM2UyCvGdZ5ETpE8na19H0LqUB6826c-JaPlaLr8M12eTJej6cTRE9cPh38iP0AUicE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P1856Percutaneous mitral edge-to-edge valvuloplasty in end-stage heart failure as a bridge to heart transplant: a case series from a single tertiary referral center</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Montalto, C ; Crimi, G ; Mandurino-Mirizzi, A ; Frassica, R ; Gazzoli, F ; Covi, R ; Moschella, M ; Ghio, S ; Magrini, G ; Raineri, C ; Pelenghi, S ; Ferrario, M ; De Ferrari, G M ; Oltrona-Visconti, L</creator><creatorcontrib>Montalto, C ; Crimi, G ; Mandurino-Mirizzi, A ; Frassica, R ; Gazzoli, F ; Covi, R ; Moschella, M ; Ghio, S ; Magrini, G ; Raineri, C ; Pelenghi, S ; Ferrario, M ; De Ferrari, G M ; Oltrona-Visconti, L</creatorcontrib><description>Abstract Background Improved outcomes after percutaneous edge-to-edge mitral valvuloplasthy with MitraClip implantation were recently observed in patients with heart failure (HF) and functional severe mitral regurgitation (MR). Nonetheless, its efficacy in end-stage heart failure (HF) are lacking. Purpose Our aim was to investigate feasibility, preliminary efficacy on hemodynamics and follow-up of MitraClip implantation in a cohort of patients with very advanced HF. Methods Patients were retrospectively included in the present analysis if already in HT list, unsuitable for HT despite optimal medical and device therapy, or if implantation was a “bridge-to-candidacy”. Results Baseline and procedural characteristics are listed in Table 1; MR etiology was predominantly functional (n=7). No major complications were observed in the peri-operative period. At 6-month follow-up, invasive hemodynamics was available for 8 patients. A significant increase in cardiac index was observed (Least Square Mean Difference, LSMD = +0.47 L/min/m2; p=0.03; Figure 1), in conjunction with a numerical reduction in pulmonary vascular resistance (LSMD = −1.02 WU; p=0.3), a trend towards lower mean pulmonary arterial pressure (LSMD = −6.5 mmHg; p=0.053) and lower ejection fraction (LSMD = −6.5%; p=0.053). At a median follow-up of 772 days (IQR 156–1,578), all three patients unsuitable for HT at baseline could be eligible to HT list and one of them received LVAD. Moreover, two patients were transplanted, four experienced unplanned rehospitalization for HF, and one died of non-cardiac cause. Table 1. Baseline clinical evaluation (n=10) Age (y) 53.67±8.43 HF Etiology – post ischemic 4 (40) Male sex 6 (60) HF Etiology – no CAD 4 (40) Body Surface Area (m2) 1.76±0.22 HF Etiology – other 2 (20) Chronic Resynchronization Therapy 5 (50) Euroscore II 6.00±2.74 Baseline MR grade (+) 4 (40) STS mortality 1.71±2.65 Residual MR grade (+) 1.71±0.49 Clips implanted (number) 1.78±0.67 Data are expressed as mean ± SD or count (valid %). MR scored on a scale from 0+ to 4+. STS, Society of Thoracic Surgeons. Figure 1 Conclusions Percutaneous edge-to-edge mitral valvuloplasty with MitraClip appears safe and effective in end-stage patients, impacts on clinical decision-making and therefore might be considered as a “bridge” towards a more definite strategy. Acknowledgement/Funding None</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehz748.0607</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2019-10, Vol.40 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27903,27904</link.rule.ids></links><search><creatorcontrib>Montalto, C</creatorcontrib><creatorcontrib>Crimi, G</creatorcontrib><creatorcontrib>Mandurino-Mirizzi, A</creatorcontrib><creatorcontrib>Frassica, R</creatorcontrib><creatorcontrib>Gazzoli, F</creatorcontrib><creatorcontrib>Covi, R</creatorcontrib><creatorcontrib>Moschella, M</creatorcontrib><creatorcontrib>Ghio, S</creatorcontrib><creatorcontrib>Magrini, G</creatorcontrib><creatorcontrib>Raineri, C</creatorcontrib><creatorcontrib>Pelenghi, S</creatorcontrib><creatorcontrib>Ferrario, M</creatorcontrib><creatorcontrib>De Ferrari, G M</creatorcontrib><creatorcontrib>Oltrona-Visconti, L</creatorcontrib><title>P1856Percutaneous mitral edge-to-edge valvuloplasty in end-stage heart failure as a bridge to heart transplant: a case series from a single tertiary referral center</title><title>European heart journal</title><description>Abstract Background Improved outcomes after percutaneous edge-to-edge mitral valvuloplasthy with MitraClip implantation were recently observed in patients with heart failure (HF) and functional severe mitral regurgitation (MR). Nonetheless, its efficacy in end-stage heart failure (HF) are lacking. Purpose Our aim was to investigate feasibility, preliminary efficacy on hemodynamics and follow-up of MitraClip implantation in a cohort of patients with very advanced HF. Methods Patients were retrospectively included in the present analysis if already in HT list, unsuitable for HT despite optimal medical and device therapy, or if implantation was a “bridge-to-candidacy”. Results Baseline and procedural characteristics are listed in Table 1; MR etiology was predominantly functional (n=7). No major complications were observed in the peri-operative period. At 6-month follow-up, invasive hemodynamics was available for 8 patients. A significant increase in cardiac index was observed (Least Square Mean Difference, LSMD = +0.47 L/min/m2; p=0.03; Figure 1), in conjunction with a numerical reduction in pulmonary vascular resistance (LSMD = −1.02 WU; p=0.3), a trend towards lower mean pulmonary arterial pressure (LSMD = −6.5 mmHg; p=0.053) and lower ejection fraction (LSMD = −6.5%; p=0.053). At a median follow-up of 772 days (IQR 156–1,578), all three patients unsuitable for HT at baseline could be eligible to HT list and one of them received LVAD. Moreover, two patients were transplanted, four experienced unplanned rehospitalization for HF, and one died of non-cardiac cause. Table 1. Baseline clinical evaluation (n=10) Age (y) 53.67±8.43 HF Etiology – post ischemic 4 (40) Male sex 6 (60) HF Etiology – no CAD 4 (40) Body Surface Area (m2) 1.76±0.22 HF Etiology – other 2 (20) Chronic Resynchronization Therapy 5 (50) Euroscore II 6.00±2.74 Baseline MR grade (+) 4 (40) STS mortality 1.71±2.65 Residual MR grade (+) 1.71±0.49 Clips implanted (number) 1.78±0.67 Data are expressed as mean ± SD or count (valid %). MR scored on a scale from 0+ to 4+. STS, Society of Thoracic Surgeons. Figure 1 Conclusions Percutaneous edge-to-edge mitral valvuloplasty with MitraClip appears safe and effective in end-stage patients, impacts on clinical decision-making and therefore might be considered as a “bridge” towards a more definite strategy. Acknowledgement/Funding None</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkE1qwzAQRkVpoWnaIxR0ASWSLMlWdyX0DwLNIovujGyPEgXHDpJcSM_Tg1ZuQtddDczHm_l4CN0zOmNUZ3MY_BaMj7s5bL9yUcyoovkFmjDJOdFKyEs0oUxLolTxcY1uQthRSgvF1AR9r1gh1Qp8PUTTQT8EvHfRmxZDswESezJO_Gnaz6HtD60J8Yhdh6FrSIgmRb-vsTWuHTxgE7DBlXcjFPtzmO51IbFdfEhpbQLgAN5BwNb3-7QKrtu0CQAfnfFH7MGCH0vU0KXlLbqypg1wd55TtH5-Wi9eyfL95W3xuCR1keeEQ0GFEBxMpaQ2vLEghRay0rbKeJ5Vtqip0AqyrOGy0LaprM2UyCvGdZ5ETpE8na19H0LqUB6826c-JaPlaLr8M12eTJej6cTRE9cPh38iP0AUicE</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Montalto, C</creator><creator>Crimi, G</creator><creator>Mandurino-Mirizzi, A</creator><creator>Frassica, R</creator><creator>Gazzoli, F</creator><creator>Covi, R</creator><creator>Moschella, M</creator><creator>Ghio, S</creator><creator>Magrini, G</creator><creator>Raineri, C</creator><creator>Pelenghi, S</creator><creator>Ferrario, M</creator><creator>De Ferrari, G M</creator><creator>Oltrona-Visconti, L</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191001</creationdate><title>P1856Percutaneous mitral edge-to-edge valvuloplasty in end-stage heart failure as a bridge to heart transplant: a case series from a single tertiary referral center</title><author>Montalto, C ; Crimi, G ; Mandurino-Mirizzi, A ; Frassica, R ; Gazzoli, F ; Covi, R ; Moschella, M ; Ghio, S ; Magrini, G ; Raineri, C ; Pelenghi, S ; Ferrario, M ; De Ferrari, G M ; Oltrona-Visconti, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c877-2e804442eab659a2dfe54945b9fb3273bf8c0496e33d2589fdbff3647b1297093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Montalto, C</creatorcontrib><creatorcontrib>Crimi, G</creatorcontrib><creatorcontrib>Mandurino-Mirizzi, A</creatorcontrib><creatorcontrib>Frassica, R</creatorcontrib><creatorcontrib>Gazzoli, F</creatorcontrib><creatorcontrib>Covi, R</creatorcontrib><creatorcontrib>Moschella, M</creatorcontrib><creatorcontrib>Ghio, S</creatorcontrib><creatorcontrib>Magrini, G</creatorcontrib><creatorcontrib>Raineri, C</creatorcontrib><creatorcontrib>Pelenghi, S</creatorcontrib><creatorcontrib>Ferrario, M</creatorcontrib><creatorcontrib>De Ferrari, G M</creatorcontrib><creatorcontrib>Oltrona-Visconti, L</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montalto, C</au><au>Crimi, G</au><au>Mandurino-Mirizzi, A</au><au>Frassica, R</au><au>Gazzoli, F</au><au>Covi, R</au><au>Moschella, M</au><au>Ghio, S</au><au>Magrini, G</au><au>Raineri, C</au><au>Pelenghi, S</au><au>Ferrario, M</au><au>De Ferrari, G M</au><au>Oltrona-Visconti, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P1856Percutaneous mitral edge-to-edge valvuloplasty in end-stage heart failure as a bridge to heart transplant: a case series from a single tertiary referral center</atitle><jtitle>European heart journal</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>40</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Background Improved outcomes after percutaneous edge-to-edge mitral valvuloplasthy with MitraClip implantation were recently observed in patients with heart failure (HF) and functional severe mitral regurgitation (MR). Nonetheless, its efficacy in end-stage heart failure (HF) are lacking. Purpose Our aim was to investigate feasibility, preliminary efficacy on hemodynamics and follow-up of MitraClip implantation in a cohort of patients with very advanced HF. Methods Patients were retrospectively included in the present analysis if already in HT list, unsuitable for HT despite optimal medical and device therapy, or if implantation was a “bridge-to-candidacy”. Results Baseline and procedural characteristics are listed in Table 1; MR etiology was predominantly functional (n=7). No major complications were observed in the peri-operative period. At 6-month follow-up, invasive hemodynamics was available for 8 patients. A significant increase in cardiac index was observed (Least Square Mean Difference, LSMD = +0.47 L/min/m2; p=0.03; Figure 1), in conjunction with a numerical reduction in pulmonary vascular resistance (LSMD = −1.02 WU; p=0.3), a trend towards lower mean pulmonary arterial pressure (LSMD = −6.5 mmHg; p=0.053) and lower ejection fraction (LSMD = −6.5%; p=0.053). At a median follow-up of 772 days (IQR 156–1,578), all three patients unsuitable for HT at baseline could be eligible to HT list and one of them received LVAD. Moreover, two patients were transplanted, four experienced unplanned rehospitalization for HF, and one died of non-cardiac cause. Table 1. Baseline clinical evaluation (n=10) Age (y) 53.67±8.43 HF Etiology – post ischemic 4 (40) Male sex 6 (60) HF Etiology – no CAD 4 (40) Body Surface Area (m2) 1.76±0.22 HF Etiology – other 2 (20) Chronic Resynchronization Therapy 5 (50) Euroscore II 6.00±2.74 Baseline MR grade (+) 4 (40) STS mortality 1.71±2.65 Residual MR grade (+) 1.71±0.49 Clips implanted (number) 1.78±0.67 Data are expressed as mean ± SD or count (valid %). MR scored on a scale from 0+ to 4+. STS, Society of Thoracic Surgeons. Figure 1 Conclusions Percutaneous edge-to-edge mitral valvuloplasty with MitraClip appears safe and effective in end-stage patients, impacts on clinical decision-making and therefore might be considered as a “bridge” towards a more definite strategy. Acknowledgement/Funding None</abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehz748.0607</doi></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2019-10, Vol.40 (Supplement_1)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_eurheartj_ehz748_0607
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title P1856Percutaneous mitral edge-to-edge valvuloplasty in end-stage heart failure as a bridge to heart transplant: a case series from a single tertiary referral center
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T10%3A43%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P1856Percutaneous%20mitral%20edge-to-edge%20valvuloplasty%20in%20end-stage%20heart%20failure%20as%20a%20bridge%20to%20heart%20transplant:%20a%20case%20series%20from%20a%20single%20tertiary%20referral%20center&rft.jtitle=European%20heart%20journal&rft.au=Montalto,%20C&rft.date=2019-10-01&rft.volume=40&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehz748.0607&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehz748.0607%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehz748.0607&rfr_iscdi=true